These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1791768)

  • 1. Dydrogesterone to oppose the 100 mg oestradiol implant.
    Greenwood PA; Jesinger DK
    Maturitas; 1991 Dec; 14(1):17-21. PubMed ID: 1791768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A first study to compare two dosages of dydrogesterone in opposing the 50 mg oestradiol implant.
    Rees M; Leather A; Pryse-Davies J; Collins SA; Barlow DH; Studd JW
    Maturitas; 1991 Dec; 14(1):9-15. PubMed ID: 1791775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone.
    Ferenczy A; Gelfand MM
    Maturitas; 1997 Apr; 26(3):219-26. PubMed ID: 9147354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial safety of continuous combined hormone replacement therapy with 17beta-oestradiol (1 or 2 mg) and dydrogesterone.
    Bergeron C; Ferenczy A
    Maturitas; 2001 Jan; 37(3):191-9. PubMed ID: 11173181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile.
    Quereux C; Pornel B; Bergeron C; Ferenczy A
    Maturitas; 2006 Feb; 53(3):299-305. PubMed ID: 16043317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.
    van de Weijer PH; Scholten PC; van der Mooren MJ; Barentsen R; Kenemans P
    Climacteric; 1999 Jun; 2(2):101-9. PubMed ID: 11910662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone.
    Ferenczy A; Gelfand MM; van de Weijer PH; Rioux JE
    Climacteric; 2002 Mar; 5(1):26-35. PubMed ID: 11974556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol.
    Burch DJ; Spowart KJ; Jesinger DK; Randall S; Smith SK
    Br J Obstet Gynaecol; 1995 Mar; 102(3):243-8. PubMed ID: 7794851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate.
    Bergeron C; Nogales FF; Rechberger T; Tatarchjuk T; Zipfel L
    Maturitas; 2010 Jun; 66(2):201-5. PubMed ID: 20378287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the withdrawal bleeding pattern and endometrial histology during 17 beta-estradiol-dydrogesterone therapy in postmenopausal women: a 2 year prospective study.
    van der Mooren MJ; Hanselaar AG; Borm GF; Rolland R
    Maturitas; 1994 Dec; 20(2-3):175-80. PubMed ID: 7715470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
    Godsland IF; Manassiev NA; Felton CV; Proudler AJ; Crook D; Whitehead MI; Stevenson JC
    Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
    van der Mooren MJ; Demacker PN; Thomas CM; Borm GF; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):117-23. PubMed ID: 8157140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch.
    Hirvonen E; Cacciatore B; Wahlström T; Rita H; Wilén-Rosenqvist G
    Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():26-31. PubMed ID: 9389780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women.
    Hänggi W; Lippuner K; Jaeger P; Birkhäuser MH; Horber FF
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):691-9. PubMed ID: 9713556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women.
    Soranna L; Cucinelli F; Perri C; Muzj G; Giuliani M; Villa P; Lanzone A
    J Endocrinol Invest; 2002 Jun; 25(6):547-50. PubMed ID: 12109627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone.
    Siddle NC; Fraser D; Whitehead MI; Jesinger DK; Endacott J; Prescott P; Pryse-Davies J
    Br J Obstet Gynaecol; 1990 Dec; 97(12):1101-7. PubMed ID: 2177648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
    Stevenson JC; Durand G; Kahler E; Pertyński T
    Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women.
    Cameron ST; Critchley HO; Glasier AF; Williams AR; Baird DT
    Br J Obstet Gynaecol; 1997 Oct; 104(10):1184-90. PubMed ID: 9332998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
    Cieraad D; Conradt C; Jesinger D; Bakowski M
    Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.